CD20 expression levels correlate with outcomes in B-cell lymphoma patients treated with CD20xCD3 bispecific antibodies. Patients with reduced CD20 expression had significantly lower PFS and OS rates ...
Patients with undetectable CD20 expression had worse outcomes with bispecific antibodies for DLBCL, highlighting the importance of target antigen expression in predicting treatment success. Real-world ...
PLEASANTON, Calif. & NANJING, China & SHANGHAI--(BUSINESS WIRE)--IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company advancing the development of novel cell therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback